MDCAT Biology

16 Biotechnology
• Biotechnology involves the application of biological processes for human
benefit.
• It has led to the development of safer, more effective treatments and
diagnostics.
• This chapter will explore how biotechnology has revolutionized healthcare.
• Key areas of impact include:

a) Modern vaccines development.

b) Highly accurate diagnostic methods.
c) Creation of life-saving medicines.

16.1 Combatting Health Problems with Modern Vaccines

A vaccine is a biological preparation that provides active acquired immunity to a
particular infectious disease. It typically contains an agent, called an antigen, that
resembles a disease-causing microorganism. This antigen stimulates the body's
immune system to recognize the agent as a threat, destroy it, and "remember" it,
allowing for a swift and effective defense against future infections.

Traditional vaccines, while revolutionary, sometimes carried risks or were difficult to

produce. Biotechnology has opened up new, safer, and more efficient avenues for
vaccine development by focusing on just the antigenic part of a pathogen, without
exposing the patient to the whole, potentially dangerous organism.

How Biotechnology Revolutionized Vaccine

The three primary biotechnological approaches are:

1. Synthesis of a Pure Antigen using Monoclonal Antibodies:

o Concept: Pathogens have many proteins, but only some trigger a strong immune
response. The goal is to isolate only the most effective antigen.

o Method: A highly specific tool called a monoclonal antibody (which we will discuss in
detail later) acts like a "magic hook," binding to and pulling only the desired antigen out
of a complex mixture of pathogen components.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

o Result: This yields a pure subunit vaccine that is much safer than
using the whole pathogen.

2. Synthesis of an Antigen from a Cloned Gene:

o Concept: Instead of isolating the antigen, we can find the gene that
codes for it and use another organism (like bacteria or yeast) as a "factory"
to produce it in large quantities.

o Method:

▪ The gene for the desired antigen is identified and isolated.

▪ This gene is inserted into a vector (like a plasmid) to create

recombinant DNA.

▪ The recombinant DNA is introduced into a host organism (e.g., E. coli

or yeast).

▪ The host cells are grown in large vats called bioreactors, where they
express the foreign gene and produce the pure antigen.

o Example: The vaccine for Hepatitis B is a famous example. It was the

first vaccine produced by genetic engineering approved for human use. The
gene for the surface antigen is expressed in
Mnemonic: Vaccine Production Methods
yeast, ensuring the final product contains no
Remember the three main biotech
viral DNA and cannot cause an infection.
methods with: "Pure-Gene-Peptide"

3. Synthesis of Peptides as Vaccines: • Pure: Purifying the antigen with

monoclonal antibodies.
o Concept: Sometimes, the entire
antigen protein isn't needed. A small, • Gene: Using a cloned gene to
make the antigen.
specific part of the protein, called a peptide,
is enough to trigger an immune response. Peptide: Synthesizing a peptide (protein
fragment) to act as the antigen.
o Method: Scientists identify the
exact amino acid sequence of the crucial
part of an antigen and synthesize this peptide chemically in a lab.

o Result: This produces a highly specific, safe, and stable vaccine that
contains no extra biological material, minimizing the risk of side effects.

16.2 The Role of Biotechnology in Disease Diagnosis

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology
Early and accurate diagnosis is critical for effective disease treatment. The
two main pillars of biotech diagnostics are DNA/RNA Probes and Monoclonal
Antibodies.

Monoclonal Antibodies (mAbs): The Magic Bullets of Diagnosis

• Polyclonal Response: The body's natural response to a pathogen is to

produce a wide variety of antibodies targeting different sites
(epitopes) on the pathogen. This is called a polyclonal response.

• Monoclonal Antibodies (mAbs): In a lab, scientists can create a large batch of

identical antibodies that all bind to a single, specific epitope. This makes them
incredibly precise. They are called monoclonal because they are produced by a clone
of a single parent immune cell.

How are mAbs Made? (Somatic Cell Hybridization)

The technique, developed in 1975, fuses a short-lived antibody-producing cell with a

long-lived cancer cell to create an "immortal antibody factory."

1. Immunization: A mouse is immunized with a specific antigen.

2. Fusion: mouse's antibody-producing spleen cells (B-lymphocytes) are fused with

"immortal" myeloma cells (cancerous B-lymphocytes).

3. Creation of Hybridoma:sThe resulting fused cell is a hybridoma. It produces a

specific antibody and can divide indefinitely.

4. Screening and Cloning: The hybridomas are screened to find the one producing the
desired antibody, which is then cloned to produce mAbs in vast quantities.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

Application in Diagnosis:

• Detecting Infections: Detecting

viral (Herpes) or bacterial proteins.

• Detecting Hormones: Used in

pregnancy tests to detect the
hormone hCG.

• Cancer Diagnosis: Detecting

specific tumor markers in the blood.

• Tissue Matching: Used in organ

transplantation to match donor and
How Do DNA Work? recipient tissues.
The principle is hybridization—the
natural tendency of complementary
DNA/RNA strands to pair up.

1. Design and Labeling: A labeled

probe complementary to the target
gene (e.g., from the Polio virus) is
created.

2. Sample Preparation: Patient DNA is

isolated and denatured (separated
into single strands) using heat.

3. Hybridization: The labeled probe is

added to the patient's DNA. If the
target gene is present, the probe binds to it.

4. Detection: Unbound probes are washed away, and the signal from the
bound probe is detected, indicating a positive result.

Applications in Diagnosis:

• Infections: Detects genetic material from viruses like Polio, Herpes, and
Hepatitis.

• Prenatal Diagnosis: Screens fetuses for genetic diseases by detecting

markers like Short Tandem Repeats (STRs)

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology
• Genetic Predisposition: Identifies alleles associated with a higher risk for
diseases like cancer.

Board-Specific Highlights (Diagnosis)

• Probe Details (Sindh Board): It is specified that DNA probes are typically
100-1000 bases long and are highly sensitive, capable of diagnosing infections
caused by protozoa and helminths.

• Laboratory Markers (Cambridge Board): For research diagnostics, specific

marker genes are used to identify modified cells. These include GFP (Green
Fluorescent Protein) from jellyfish, making cells glow green, and the GUS gene,
which produces a blue color, acting as a visual confirmation.

• Ethical Context (Cambridge Board): The history and ethics of diagnosis are
explored, citing the first 'designer baby' via Pre-implantation Genetic Diagnosis
(PGD) in 1989 and the successful thalassemia screening programs in Mediterranean
countries as case studies.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

16.3 Products for Disease Treatment

Biotechnology's greatest impact lies in creating novel treatments, from mass-
producing essential proteins to correcting faulty genes at their source. This process
is often called biopharming.

Therapeutic Proteins: Using Living Factories

Many diseases result from the body's inability to produce a specific protein. Using
recombinant DNA technology, we can turn simple organisms into "protein factories."

1. Production in Transgenic Bacteria

(e.g., E. coli) Mnemonic: Bacterial Drug Production

" I Help Fight Clots and Grow"

This is the most established method. The
human gene is inserted into a bacterial plasmid, • I: Insulin
and the bacteria produce the protein in large
• H: Hemophilia Factors (Help)
bioreactors.
• F: Interferons (Fight)
• Human Insulin: Treats diabetes, eliminating the
allergic reactions some patients had to pig or • C: Clots (tPA)

cow insulin. • G: Growth Hormone

• Human Growth Hormone (HGH): Treats

pituitary dwarfism.

• Interferons: Treat viral infections (like hepatitis) and some cancers.

• Tissue Plasminogen Activator (tPA): A powerful "clot-buster" for heart attacks.

• Clotting Factors (e.g., Factor VIII): Treat hemophilia, avoiding the risk of
transmitting blood-borne diseases like HIV from human donors..

2. Production in Transgenic Animals (Gene Pharming)

For complex proteins, scientists use transgenic animals. The human gene is micro-
injected into a fertilized animal egg, which is then implanted into a surrogate
mother. The resulting female offspring produces the therapeutic protein in its milk.

• Antithrombin III: Produced in the milk of transgenic goats to prevent blood clots.

• Alpha-1-Antitrypsin (AAT): Produced in sheep's milk to treat emphysema.

Gene Therapy: Correcting the Source Code of Disease

Gene therapy aims to treat or cure genetic disorders by correcting the faulty genes
themselves.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology
Approaches to Correcting Faulty Genes:

• Gene Insertion (Augmentation): A normal, functional gene is added to the genome.

This is the most common approach.

• Gene Replacement: The abnormal gene is swapped for a normal gene.

• Gene Repair: The abnormal gene itself is repaired through reverse mutation.

• Altering Gene Regulation: The regulation of a gene is changed (e.g., switching a needed
gene "on").

Methods and Vectors

A vector (carrier molecule) is used to
transport the therapeutic gene into a
patient's cells.

• Ex vivo Gene Therapy: cells are taken from the patient (e.g., bone marrow stem cells), modified in
the lab, and then returned.

• In vivo Gene Therapy: The vector is delivered directly into the patient's body (e.g., via aerosol
spray to the lungs).

• Vectors:
o Viral Vectors
(Retroviruses,
Adenoviruses:
Viruses are
natural experts at
injecting genes.
They are modified
to be harmless.
Retroviruses offer
a permanent fix
but risk causing
cancer
(insertional
mutagenesis). Adenoviruses are safer but temporary.

o Non-Viral Vectors (Liposomes): These microscopic lipid spheres are safer than viruses but
less efficient at delivering genes.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

Key Examples & Challenges:

• SCID (Severe Combined Immunodeficiency): Ex vivo therapy successfully restored

immune function in "bubble boy" patients, but early trials highlighted the risk of
insertional mutagenesis from retroviruses.
• Cystic Fibrosis (CF): In vivo therapy using nasal sprays has been attempted.
However, challenges remain in achieving efficient, lasting gene delivery to lung cells.

Board-Specific Highlights (Treatment and Production)

• Terminology (Sindh Board): In addition to gene pharming, animals used to produce

pharmaceuticals are sometimes called "transpharmer animals."
• Key Historical Milestones (Punjab Board): The successful cloning of Dolly the
sheep in 1997 at the Roslin Institute is often cited as a landmark event,
demonstrating the potential to create identical copies of a genetically valuable
animal for gene pharming.
• Future of Gene Therapy (Cambridge Board): CRISPR gene-editing technology is
highlighted as a powerful and precise tool that represents the future of gene
therapy, moving beyond just adding genes to actually editing the genome directly.
• Unique Animal Gene Delivery Method (Punjab Board): Besides micro-injection,
vortex mixing of eggs with DNA and silicon-carbide needles is mentioned as a
method for creating transgenic animals.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

Biotechnology Overview:
Biotechnology applies biological processes for human benefit, improving healthcare by developing
safer, more effective treatments and diagnostics. It focuses on combating health problems with
modern vaccines, diagnostic techniques, and creating life-saving medicines.

1. Combatting Health Problems with Modern Vaccines:

• Vaccines: Biological preparations that provide immunity by stimulating the immune system. Modern
vaccines focus on using antigens from pathogens, minimizing risk compared to traditional vaccines.

Biotechnological Approaches:

o Monoclonal Antibodies: Isolate the most effective antigens by using antibodies to bind and extract
them.

o Cloned Gene Antigens: Isolate the gene coding for the antigen, insert it into a host organism like
bacteria or yeast, which then produces the antigen.

o Peptide Vaccines: Use small parts of the antigen protein to stimulate an immune response, reducing
side effects.

2. Biotechnology in Disease Diagnosis:

• Monoclonal Antibodies (mAbs): Produced by fusing immune cells with cancer cells to create
"immortal" antibody-producing cells. mAbs are used for precise diagnostics in infections, cancers,
and tissue matching.

• DNA/RNA Probes: Used to detect genetic material from pathogens, such as viruses like Polio,
Herpes, and Hepatitis, as well as to identify genetic predispositions like cancer risk.

3. Products for Disease Treatment:

• Biopharming: Biotechnology in drug production, including using bacteria and transgenic animals to
produce therapeutic proteins.

o Human Insulin: Produced by genetically engineered bacteria to treat diabetes.

o Growth Hormones: Treats growth deficiencies.

o Gene Therapy: Aims to correct genetic disorders by inserting, replacing, or repairing faulty genes.
It can be done ex vivo (outside the body) or in vivo (directly in the body using vectors like viruses or
liposomes).

o Transgenic Animals: Used to produce complex proteins in their milk, such as antithrombin III and
alpha-1-antitrypsin.

4. Challenges and Future Directions:

• Gene therapy faces challenges in delivering genes effectively and safely.

• New technologies like CRISPR are being explored to directly edit genes, offering a more precise
approach to treatment.

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology

Final Challenge MCQs

These questions are designed to test your ability to integrate and apply concepts
from across the entire chapter.

1. A patient is diagnosed with a genetic disorder caused by a faulty recessive

allele that leads to a missing enzyme in liver cells. Which of the following
describes the most precise, modern therapeutic approach discussed in this
chapter?
(A) Lifelong injections of polyclonal antibodies derived from a mouse immunized with
the enzyme.
(B) Ex vivo gene therapy, where liver cells are removed, treated with a liposome
vector carrying the correct gene, and re-implanted.
(C) A vaccine containing a peptide sequence from the missing enzyme to stimulate
the body to produce it.
(D) Regular transfusions of the enzyme, produced by transgenic E. coli expressing
the human gene.

2. What is a fundamental difference between using a monoclonal antibody for

diagnosis and using a viral vector for in vivo gene therapy?
(A) The antibody is a protein that targets another protein, while the vector is a
particle that delivers a nucleic acid.
(B) The antibody must enter the nucleus to function, while the vector binds to the
cell surface.
(C) The antibody is part of a polyclonal response, while the vector is a monoclonal
product.
(D) The antibody works inside the body, while the vector is only used in a lab.

3. For Cystic Fibrosis (CF), a DNA probe could be used to diagnose the presence
of the faulty CFTR allele in a fetus. How does this diagnostic process
fundamentally differ from the goal of gene therapy for CF?
(A) The probe identifies genetic information, while gene therapy aims to change
genetic information.
(B) The probe uses hybridization, while gene therapy uses protein synthesis.
(C) The probe is administered ex vivo, while gene therapy for CF is in vivo.
(D) The probe targets RNA, while gene therapy targets proteins.

4. A scientist successfully treats SCID using ex vivo gene therapy. To confirm the
treatment's success at the molecular level over time, what would be the best
diagnostic test to run periodically?

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology
(A) Use a DNA probe for the retrovirus to see if it is still present.
(B) Use a monoclonal antibody test to quantify the level of ADA enzyme in the blood.
(C) Perform another gene therapy session to see if the patient's condition improves
further.
(D) Sequence the patient's entire genome to look for mutations.

5. A company is deciding whether to produce a complex human glycoprotein (a protein with

sugars attached) using transgenic E. coli or transgenic goats (gene pharming). Why
might the goat be a better choice?
(A) Bacteria reproduce much faster, leading to higher yields.
(B) It is easier to insert a human gene into a goat egg than a bacterial plasmid.
(C) Goat cells (eukaryotic) can perform the necessary post-translational modifications (like
adding sugars), while bacterial cells (E. coli, prokaryotic) cannot.
(D) The risk of viral contamination is zero with goats but high with bacteria

Final Challenge Answers & Explanations:

1. (D) Regular transfusions of the enzyme, produced by transgenic E. coli expressing the
human gene. This is the most established, safest, and most precise modern therapeutic
approach described.

o (A) is incorrect because polyclonal antibodies are not used for this, and they don't
replace an enzyme.

o (B) describes gene therapy, which is still largely experimental and less established
than protein production.

o (C) describes a vaccine, which stimulates an immune response but cannot make the
body produce a gene it genetically lacks.

2. (A) The antibody is a protein that targets another protein, while the vector is a
particle that delivers a nucleic acid. This is the core difference.

o For diagnosis, the mAb (a protein) binds to the target antigen (a protein).

o For therapy, the vector (e.g., a virus particle) carries DNA/RNA into a cell.

o (B) is incorrect; antibodies bind to the outside or inside of cells, but vectors must
deliver their payload into the nucleus. (C) is incorrect as both can be monoclonal
products. (D) is incorrect; both can be used inside the body.

3. (A) The probe identifies genetic information, while gene therapy aims to change
genetic information. This is the fundamental distinction. Diagnosis is about reading

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734

 Biotechnology
the genetic code; therapy is about rewriting or adding to it. The other options
describe aspects of the processes but not the core difference in their goals.

4. (B) Use a monoclonal antibody test to quantify the level of ADA enzyme in the
blood. The goal of the therapy is to restore the function of the missing enzyme
(ADA). Measuring the level of this enzyme protein directly shows whether the
corrected cells are working and producing it.

o (A) confirms the presence of the vector, not its function.

o (C) is a treatment, not a diagnostic test.

o (D) is excessively expensive and unnecessary; the goal is to see if the one
corrected gene is working, not to search for random mutations.

5. (C) Goat cells (eukaryotic) can perform the necessary post-translational

modifications (like adding sugars), while bacterial cells (E. coli, prokaryotic)
cannot. Many complex human proteins, like glycoproteins, require modifications
after being synthesized to become functional. Eukaryotic systems (like goat
mammary cells) are far better at this than simple prokaryotic systems. While
bacteria reproduce faster (A), they cannot produce the final functional product in
this case.

my notes

For MDCAT 2025 Enrollment, Contact Us at: 0311-144734